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Immunological imprinting of the antibody response
in COVID-19 patients
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Jordi Carratala 3,4✉ & Adolfo García-Sastre 1,2,7,8✉
In addition to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), humans are
also susceptible to six other coronaviruses, for which consecutive exposures to antigenically
related and divergent seasonal coronaviruses are frequent. Despite the prevalence of COVID-
19 pandemic and ongoing research, the nature of the antibody response against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is unclear. Here we longitudinally profile
the early humoral immune response against SARS-CoV-2 in hospitalized coronavirus disease
2019 (COVID-19) patients and quantify levels of pre-existing immunity to OC43, HKU1 and
229E seasonal coronaviruses, and find a strong back-boosting effect to conserved but not
variable regions of OC43 and HKU1 betacoronaviruses spike protein. However, such antibody
memory boost to human coronaviruses negatively correlates with the induction of IgG and
IgM against SARS-CoV-2 spike and nucleocapsid protein. Our findings thus provide evidence
of immunological imprinting by previous seasonal coronavirus infections that can potentially
modulate the antibody profile to SARS-CoV-2 infection.
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S ince January 2020, the Severe Acute Respiratory SyndromeCoronavirus 2 (SARS-CoV-2) virus has been spreadingglobally causing the first documented pandemic of cor-
onavirus in history1,2. SARS-CoV-2 is a betacoronavirus that
belongs to a large family of viruses capable to infect both mam-
mals and birds. Humans are susceptible to at least other six
viruses from the genus alpha and betacoronavirus3. All of them
typically cause respiratory illness but to a different extent. While
SARS-CoV-1 and Middle East Respiratory Syndrome Cor-
onavirus, are highly pathogenic betacoronaviruses that have
caused zoonotic outbreaks in humans in the last 20 years4,5, the
alphacoronaviruses 229E and NL63, and the betacoronaviruses
OC43 and HKU1, frequently cause mild upper respiratory tract
disease and have been circulating in humans as seasonal
viruses3,6. The ongoing pandemic of coronavirus disease 2019
(COVID-19), the disease caused by SARS-CoV-2, is still chal-
lenging healthcare systems and the research community. SARS-
CoV-2 can cause a different range of clinical manifestations, from
asymptomatic to severe respiratory syndrome. However, a high
percentage of severe cases have been reported and estimated
numbers of patients that succumbed to COVID-19 disease are
more than 3 million according to WHO as May 20212,7 (https://
covid19.who.int/). Many vaccine candidates are being tested in
clinical trials and several have already been authorized for use in
the population8–10. However, we are still in an early phase and
studies regarding vaccine effectiveness in special populations are
needed. Similarly, longevity of the humoral immunity after
infection and vaccination is still an ongoing debate.
One of the main targets of antibody responses to coronaviruses
is the spike, the surface glycoprotein that mediates attachment to
the host receptor and membrane fusion. Two subunits can be
identified, the S1 subunit containing the receptor-binding domain
(RBD), essential for binding to the entry receptor11–13; and the
S2 subunit, responsible of virus cell fusion14. Different human
coronaviruses use different domains to bind their human recep-
tors and to mediate cell entry. While the human endemic beta-
coronaviruses OC43 and HKU1, bind to sialic acids, 229E
alphacoronavirus uses human aminopeptidase N as a cellular
determinant for susceptibility15,16. NL63, SARS-CoV, and SARS-
CoV-2, in contrast, need direct interaction with the angiotensin-
converting enzyme 2 to infect cells13,17. Therefore, antibodies
directed against the RBD of human coronaviruses are capable to
neutralize the virus15,18,19 and no cross-reactive neutralizing
antibodies among seasonal human coronavirus are expected due
to the high specificity of this process and the sequence divergence
between the RBD of these viruses20–23. In addition, the more
cross-reactive viral nucleoprotein (N) has also shown to be
immunogenic and induce antibodies in COVID-19 patients.
However, in contrast to RBD antibodies, N antibodies are not
able to neutralize the virus in tissue culture11,23,24.
Several studies have demonstrated that T cells can recognize
homologous epitopes shared between different endemic
coronaviruses25–30. However, serum cross-reactivity between
conserved epitopes from SARS-CoV-2 and seasonal human cor-
onaviruses is still under investigation23,31–33 and the role of pre-
existing humoral immunity and immunodominance for B cell
responses needs to be addressed. Immune imprinting (or original
antigenic sin), refers to the preference of the immune system to
recall existing memory cells, rather than stimulating de novo
responses when encountering a novel but closely related
antigen34. This has been shown for viruses like influenza virus, in
which subsequent infections with antigenically related strains
produce a recall response or ‘back-boosting’ that generates an
increase in antibody titers toward epitopes shared between the
current and the historic strains encountered earlier in life35–38.
Boost of cross-reactive antibody responses can also occur for
viruses like dengue virus (DENV) upon secondary infections with
a different serotype39,40. In this case, specific titers to the original
DENV were higher than those specific to the second infecting
DENV upon secondary DENV infection41,42.
Here, we profile the antibody responses of a longitudinal
cohort of hospitalized patients with COVID-19. We characterize
de novo antibody responses against SARS-CoV-2 and pre-
existing immunity against selected endemic coronavirus being
targeted by the humoral immune system to investigate the role of
immunological imprinting on COVID-19 patients’ antibody
response. We show that the induction of antibodies against
conserved epitopes of seasonal coronaviruses may hinder the
induction of specific antibodies toward divergent SARS-CoV-2
antigens. This study provides a dynamic characterization of the
co-evolving nature of antibody responses to human cor-
onaviruses, both seasonal and pandemic, and contributes to a
better understanding of cross-reactive antibody responses and B
cells immunodominance against human coronaviruses.
Results
The BACO cohort. Thirty-seven COVID-19 patients were
recruited at the University Hospital of Bellvitge during the first
wave of SARS-CoV-2 in Barcelona (Spain) from March 26, 2020
to May 28, 2020. Mean age was 65 years and 67% were male.
Chronic comorbidities were frequent among COVID-19 patients
(25, 67.7%). In particular, 16 (43.2%) of patients were obese (body
mass index >30) at the time of hospitalization. A high percentage
of patients had respiratory symptoms, such as coughing (26,
70.3%) and dyspnea (14, 37.8%), whereas diarrhea was also
present in seven (18.9%) of the patients. While no remdesivir was
available, lopinavir/ritonavir was used for 17 (45.9%) patients. All
patients, except one (36, 97.3%), developed SARS-CoV-2 viral
pneumonia and four (10.8%) required intensive care unit
admission. Five (13.5%) patients died. Demographics, clinical
characteristics, interventions, such as drug therapy and outcomes
are detailed in Table 1.
Acute blood samples were collected longitudinally in the
BACO cohort at the recruitment upon hospital admission, and at
days 3 and 7 in 33 (89.1%) and 22 (59.4%) patients, respectively.
Mean time from symptom onset to inclusion in the study was
7 days (range 2–14). Most of the patients (25, 67.5%) were
recruited within the first week of symptom onset, whereas 12
(32.4%) patients had longer periods until hospitalization.
COVID-19 survivors were followed up in the convalescence
period and 28 out of 32 survivors (87.5%) had another blood
draw after hospital discharge with a mean time of 46 days post
recruitment (range, 30–56 days).
COVID-19 patients developed anti-SARS-CoV-2 antibodies
linked to back-boosting of antibodies against S2 domain of
betacoronaviruses. To profile the early antibody response in
COVID-19 patients, we investigated the levels of neutralizing
antibodies against authentic SARS-CoV-2 virus and IgG/IgM
ELISAs against multiple antigens including the full-length spike
(S), the spike RBD S and the N of SARS-CoV-2. IgG and IgM
levels were quantified as area under the curve (AUC) by plotting
normalized optical density (OD) values against the reciprocal
serum sample dilutions for ELISAs (Supplementary Fig. 1A). To
improve visualization, the longitudinal antibody profile of each
individual patient together with the geometric mean titer (GMT,
CI 95%) at each time point is shown for AUC ELISA and neu-
tralizing titers in Fig. 1A and Supplementary Table 1. All patients
developed detectable levels of neutralizing antibodies at day 7
post recruitment while levels remained stable during the con-
valescent phase, except for two survivors. Similar responses were
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23977-1
2 NATURE COMMUNICATIONS |         (2021) 12:3781 | https://doi.org/10.1038/s41467-021-23977-1 | www.nature.com/naturecommunications
found by ELISA, although higher levels of antibodies against IgG
S compared to IgG RBD were present. When comparing to the
induction of anti-spike antibodies, the IgG isotype reached higher
titers than the IgM isotype, whereas anti-N protein IgG had
similar induction than the anti-S IgG. We then determined fold
increase of antibody titers from baseline levels. Overall, all
patients had a high induction of SARS-CoV-2 S and RBD anti-
bodies at day 7 post recruitment. IgG titers against the S and RBD
of SARS-CoV-2 remained stable at the convalescent time point
with similar levels compared to peak titers at day 7. By contrast,
IgM against the S, IgG against N and neutralizing titers against
authentic SARS-CoV-2 virus decreased to levels resembling those
at day 3. Geometric mean fold rise (GMFR) and adjusted p values
on pairwise comparisons after related samples Friedman’s two-
way ANOVA at each time points are shown Fig. 1B. We next
tested the correlation between neutralization activity and levels of
anti-SARS-CoV-2 antibodies. Scatterplot matrices shown in
Supplementary Fig. 2 indicate that the antibodies detected against
SARS-CoV-2 antigens correlated well with neutralizing activity,
with Pearson R2 ranging from 69 to 81% in the case of IgG
against the RBD S of SARS-CoV-2.
The S gene of SARS-CoV-2 is highly divergent from human
seasonal coronaviruses (hCoV). Infection with endemic hCoV in
humans happens frequently3,6,43, causing mild respiratory
disease. Multiple sequence alignment (MSA) between the S of
SARS-CoV-2 and selected seasonal coronaviruses showed amino
acid identity ranging from 28% for alphacoronaviruses (229E)
and 32.5% and 33% for betacoronaviruses (OC43 and HKU1,
respectively). To identify conserved amino acid regions, we also
estimated the relative conservation scores of the S protein of
SARS-CoV-2 using the chain A of the SARS-CoV-2 spike protein
in the closed state as a reference. MSA and relative amino acid
conservation was determined by using the ConSurf server.
Figure 2A shows the conservation score for each amino acid
position and projected on the S protein structure. Evolutionary
conservation analysis showed that the S2 subunit had the highest
degree of identity among the sequences tested. Given the high
probability of previous exposure to seasonal coronaviruses in the
BACO cohort, we screened levels of antibodies against the spike
of alphacoronavirus 229E and betacoronaviruses HKU1, OC43.
Antigens tested included full-length S protein for all three
endemic coronaviruses together with the less conserved HKU1
S1 subunit (Supplementary Fig. 3A). Remarkably, COVID-19
patients exhibited an outstanding back-boosting of antibodies to
the beta- CoV spikes tested, with similar a longitudinal profile as
the one observed for the SARS-CoV-2 spike and for SARS-CoV-2
neutralizing titers (Fig. 3A). The back-boost was higher at day 7,
with a GMFR from baseline levels of 3.8 and 4 for HKU1 S and
OC43 S, respectively (Fig. 3B, Supplementary Table 1). While IgG
levels against 229E were already high at baseline, no increase was
detected at any time point during the follow-up on patients with
COVID-19. Interesting, no back-boosting was found when we
tested antibody titers against the more divergent S1 subunit of
HKU1, pointing to an increase of immune responses towards
conserved epitopes of the S2 subunit of the spike protein of beta-
human coronaviruses. Similar to influenza viruses, HKU1 and
OC43 use sialic acids as canonical receptor to infect human
cells16. This is mediated by an additional surface protein in these
viruses with hemagglutination (HA) activity (hemagglutinin-
esterase (HE) protein). No increase in OC43 HA inhibitory
antibodies was found in COVID-19 patients, consistent with the
lack of HE in SARS-CoV-2. Longitudinal profile and fold increase
antibody titers to selected seasonal human coronaviruses antigens
are shown in Fig. 3 and Supplementary Table 1.
To test whether the antibody response characterized in the
BACO cohort correlated with disease trajectory, we grouped
patients according to disease phenotype. Patients were assigned as
mild/moderate (N= 26, 70.3%) or severe/severe end-of organ
disease (EOD, N= 11, 29.7%) based on a previously described
severity scale44. No statistically significant differences were found
between humoral immune response in patients with mild and
severe/severe EOD disease, but the latter tended to have a delay in
the antibody response towards SARS-CoV-2 antigens compared to
moderate cases (Fig. 4A). Patients with severe disease had lower Ct
values, and therefore higher viral loads (Fig. 4B). Besides, a positive
correlation was found between anti- SARS-CoV2 antibodies and
mean Ct values in paired nasopharyngeal swabs of COVID-19
patients acknowledging an interplay between antibodies and virus
control and disease severity in COVID-19 patients. However, no
correlation was found between antibodies against seasonal
coronaviruses and viral loads in the BACO Cohort (Fig. 4C).
Immunological imprinting results in a bias in the induction of
antibodies to conserved vs. variable regions of the SARS-COV-
2 spike. Given the strong back-boosting observed to the con-
served epitopes of the S domains of human betacoronaviruses in
patients with COVID-19, we next investigated whether a strong
back-boosting might reduce the induction of de novo humoral
immune responses against specific epitopes of the spike of SARS-
CoV-2 defined as fold induction over baseline levels.
Table 1 Demographics and clinical characteristics of the
BACO cohort.
Total (n= 37)
Demographics and comorbidities
Age (mean, IQR) 67 (25)
Men (n, %) 25 (67.6)
Comorbidities (n, %) 25 (67.7)
Lung disease (n, %) 7 (18.9)
Diabetes mellitus 7 (18.9)
Heart disease (n, %) 5 (13.5)
Kidney disease (n, %) 3 (8.1)
Obesity (n, %) 16 (43.2)
SOTR (n, %) 1 (2.7)
Signs and symptoms
Days from symptom onset to enrollment
(mean, range)
7.19 (2–14)
Days of fever (mean, range) 4.68 (0–12)
Throat ache (n, %) 4 (10.8)
Cough (n, %) 26 (70.3)
Dyspnea (n, %) 14 (37.8)
Diarrhea (n, %) 7 (18.9)
Sp02 < 94% (n, %) 14 (37.8)
Drug therapy
Hydroxychloroquine (n, %) 36 (97.3)
Lopinavir/Ritonavir (n, %) 17 (45.9)
Tocilizumab (n, %) 10 (27)
Antibiotics (n, %) 19 (51.4)
Corticosteroids (n, %) 18 (48.6)
Outcomes
Pneumonia (n, %) 36 (97.3)
ICU (n, %) 4 (10.8)
Days from hospitalization to ICU (mean, range) 9.5 (5–12)
Days in ICU (mean, range) 15 (15–22)
Non-mechanical ventilation (n, %) 11 (29.7)
Mechanical ventilation (n, %) 2 (5.4)
Nosocomial co-infection (n, %) 2 (5.4)
Mortality (n, %) 5 (13.5)
Days of hospitalization (mean, range) 11.2 (2–47)
SOTR solid organ transplant recipient, SpO2 < 94% pulse oximetry below 94%, ICU intensive
care unit.
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To test this hypothesis, we examined the relationship between
pre-exposure to HKU1, OC43, and 229E viruses and the
induction of SARS-CoV-2 S, RBD, and N antibodies in our
cohort, and determined Pearson correlation coefficients between
IgG levels at baseline against seasonal human coronaviruses and
the fold induction of SARS-CoV-2 antigens at days 3, 7 and
convalescence. Pearson correlation matrices according to seasonal
coronavirus subtype are shown in Fig. 5. Striking differences were
found according to virus types. While pre-existing IgG levels
against HKU1 and OC43 spike protein negatively impacted the
induction of de novo IgG and IgM against SARS-CoV-2 antigens,
including S and N protein (Fig. 5A, B), no influence was found
when testing the relationship between pre-existing anti-229E
spike IgG levels (Fig. 5D). Moreover, correlations became
stronger over time, and while this correlation was lower at day
3, a stronger correlation was found at day 7, and convalescence
time points in the surviving patients. Besides, a comparable
performance was observed when testing the subsequent induction
of the IgG antibodies against the variable RBD domain of SARS-
CoV-2 spike. This result suggests that pre-existing immunity
against seasonal betacoronaviruses biases the humoral response
towards betacoronaviruses cross-reactive antibodies in detriment
of antibodies against the more divergent and antigenically unique
domains of the S of SARS-CoV-2, such as those of the RBD
domain (Fig. 5A, B). This was also evidenced by the lack of
impact of pre-existing HKU1 S1 IgG levels (S1 is divergent and
harbors the RBD) on specific SARS-CoV-2 antibodies induction
(Fig. 5C). Thus, only the levels of antibodies against cross-reactive
epitopes of human betacoronaviruses had an effect on the
subsequent antibody response to SARS-CoV-2 unique spike
antigens. Because neutralization activity has been linked to in vivo
protection after challenge with SARS-CoV-245, we also tested if
immune imprinting could hinder the induction of neutralizing
antibodies against SARS-CoV-2. No significant correlation was
found. However, linear regression analysis determined a stan-
dardized beta coefficient of −0.32 (95% CI −0.35–0.05, p= 0.13)
and −0.31 (95% CI −0.28–0.02, p= 0.1) at day 7 and
convalescence time points, respectively, for pre-existing
HKU1 spike antibody levels approximating a negative impact of
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Fig. 1 Longitudinal antibody response to SARS-CoV-2 antigens. Serum from hospitalized COVID-19 patients was analyzed at baseline, at hospital
recruitment and days 3 and 7. A subsequent sample was collected in the convalescence period in the COVID-19 survivors with mean time of 46 days.
A Longitudinal profile of antibodies against SARS-CoV-2. Antibody titer was quantified as area under the curve (AUC) after serial serum dilution for each
sample (Supplementary Fig. 1). Calculated AUC at each time is shown to quantify changes over time for each individual (small dots) against
immunoglobulin G (IgG) spike, IgG receptor-binding domain (RBD), immunoglobulin M (IgM) spike and IgG nucleocapsid (N); and neutralizing activity
(nAb) as inhibitory concentration 50% (IC50%). Geometric mean titer (GMT, big dots) and confidence interval (CI 95%) are also shown. B Boxplot
diagram of geometric mean fold rise (GMFR) antibody titers against SARS-CoV-2 at the same time points: IgG spike, IgG RBD, IgM spike and IgG NP; and
neutralizing activity (nAb). Related-samples Friedman’s two-way ANOVA was performed. Significant adjusted p values after pairwise comparisons are
shown for each comparison. Black bar indicates GMFR values, box indicates IQR (Q1–Q3), lines indicate minimum and maximum. Outliers from the
observed distribution are shown. Total n= 116 biologically independent serum samples (day 0= 37, day 3= 29, day 7= 22, day 46= 28). n= 116
biological samples examined against four different SARS-CoV-2 substrates for ELISA assays; ELISAs for each substrate were run once each. N= 116 serum
samples examined over two independent experiments for neutralization assays.
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alignment was generated by the ConSurf algorithm (https://consurf.tau.ac.il)
using the chain A of the SARS-CoV-2 spike protein in the closed state (PDB
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ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23977-1
4 NATURE COMMUNICATIONS |         (2021) 12:3781 | https://doi.org/10.1038/s41467-021-23977-1 | www.nature.com/naturecommunications
HKU1 pre-existing immunity on induction of neutralizing
antibodies against SARS-CoV-2 in COVID-19 patients over time
(Fig. 6A). A similar trend was found for the levels of pre-existing
antibodies against the OC43 spike (Fig. 6B). Interestingly, the
impact of back-boosting on IgM against the S protein was smaller
when compared to IgG S or RBD. Scatterplots and the predicted
regression lines for the relationship of induction of antibodies
against SARS-CoV-2 and pre-exposure to betacoronaviruses are
shown in Fig. 5A–D according to time points in the longitudinal
follow-up. To assess neutralization potency according to the levels
of pre-existing levels of seasonal coronaviruses, we normalized
levels of IgG against seasonal human coronavirus antigens by the
levels of anti- spike IgG from SARS-CoV-2 virus at the same time
points. This analysis allows for comparison of high vs. low
presence of pre-existing antibodies toward OC43, 229E, or HKU1
(antibodies at baseline) against the elicitation of SARS-CoV-2
antibodies over the observation course. We then tested whether
those patients with higher hCoV/SARS-CoV-2 IgG ratio had
lower induction of neutralizing antibodies. After linear regression
analysis some disparities were found (Fig. 7). In general, the
higher hCoV/SARS-CoV-2 IgG ratio for HKU1 and OC43 IgG S
at baseline and day 3, the lower was the induction of antibodies
with neutralizing activity to SARS-CoV-2, suggesting some
limitations for the ability to elicit robust protective antibody
responses against novel antigenic epitopes of SARS-CoV-2 in
patients with high levels of cross-reactive antibodies against
circulating betacoronaviruses.
Finally, and to test whether imprinting on B cell compartment
could also influence antibody responses against more divergent
mutated spike proteins from SARS-CoV-2 variants, we measured
antibody responses against the spike protein of two SARS-CoV-2
variants. These variants, B.1.1.7 and B.1.351 emerged in late 2020
in United Kingdom and South Africa, respectively. Both B.1.1.7
and B.1.351 bear a N501Y mutation within the RBD while
B.1.351 contains also K417N, E484K changes. In addition, further
mutations can be found outside of the RBD domain. We
performed ELISA against the B.1.1.7 and B.1.351 RBDs as well as
neutralization assays against the authentic hCoV-19/England/
204820464/2020 (B.1.1.7) and hCoV-19/South Africa/KRISP-
K005325/2020 (B.1.351) variants. Interesting, when percentage
of decrease compared to the reference was calculated, we found
that responses targeting the RBD dropped from 50 to almost
100% for B.1.1.7 and B.1.351, respectively (Fig. 8A). In contrast,
neutralizing titers against B.1.1.7 were similar to USA-WA1/2020,
while percentage of decrease respect to B.1.351 was around 50%,
indicating presence of neutralizing antibodies directed against
epitopes different to those contained in the RBD, such as those
directed against the N-terminal domain (Fig. 8B). Finally, we
calculated Pearson correlation coefficients to examine the
relationship between seasonal coronavirus HKU1 and OC43
pre-existing immunity and the ELISA antibody responses against
the mutated RBDs. Pearson correlation matrices in Fig. 8C, D
shows the relationship between pre-existing antibody levels
against OC43 and HKU1 and fold induction against RBDs
containing N501Y only, or N501Y, K417N, and E484K muta-
tions. No significant correlation was found between pre-exposure
to seasonal coronaviruses and responses against the mutated
RBDs. The BACO cohort presented in here was enrolled in the
first wave of SARS-CoV-2 in Spain, and the likelihood of being
infected against a similar variant to Wuhan-Hu-1 is high. It is
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Fig. 3 Longitudinal antibody response to selected seasonal human coronaviruses antigens. Serum from hospitalized COVID-19 patients was analyzed at
baseline, at hospital recruitment and days 3 and 7. A subsequent sample was collected in the convalescence period in the COVID-19 survivors with mean
time of 46 days. A Longitudinal profile of antibodies against betacoronavirus (HKU1 and OC43) and alphacoronavirus (229E) antigens. Antibody titer was
quantified as area under the curve (AUC) after serial serum dilution for each sample (Supplementary Fig. 1). Calculated AUC at each time is shown to
quantify changes over time for each individual (small dots) against immunoglobulin G (IgG) HKU1 spike, IgG HKU1 S1, IgG OC43 spike and IgG 229E.
Geometric mean titer (GMT, big dots) and confidence interval (CI 95%) are also shown. Hemagglutination inhibition (HI) assay were also performed for
OC43 and GMT of end point titers are shown at each time point. B Boxplot diagram of geometric mean fold rise (GMFR) antibody titers against seasonal
coronaviruses at the same time points: IgG HKU1 spike, IgG HKU1 S1, IgG OC43 spike and IgG 229E; and HI titer. Related-samples Friedman’s two-way
ANOVA was performed. Significant adjusted p values after pairwise comparisons are shown for each comparison. Black bar indicates GMFR values, box
indicates IQR (Q1–Q3), lines indicate minimum and maximum. Outliers from the observed distribution are shown. Total n= 116 biologically independent
serum samples (day 0= 37, day 3= 29, day 7= 22, day 46= 28). n= 116 biological samples examined against four different seasonal coronavirus
substrates for ELISA assays; ELISAs for each substrate were run once each. N= 116 serum samples examined over two independent experiments for
hemagglutination assays.
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likely that the drop on RBD titers for the variants is responsible
for the lack of detection of an imprinting effect with these
variants.
Discussion
Our findings provide a dynamic characterization of the antibody
response to SARS-CoV-2 in COVID-19 patients and provide
evidence of immune imprinting in these patients. Our results
demonstrate back-boosting in the BACO cohort against the
conserved epitopes of the spike protein of OC43 and HKU1
betacoronaviruses. No induction was detected for the variable
regions of these viruses, such as the S1 domain, or to more
divergent seasonal alphacoronaviruses, such as 229E. Although
antibody cross-reactivity has been reported in cross-sectional
studies22,23,25,32, our cohort has allowed for quantification and
detailed representation of the longitudinal outcome of the
immune response by taking into consideration past exposure to
related antigens. Neutralization activity of antibodies might be
used as a proxy for protection against SARS-CoV-2 infection46,47.
IgG responses to the spike and RBD of SARS-CoV-2 showed
persistence over the time period of our study with slight changes
in antibody levels in convalescent sera as compared to the peak of
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antibody induction at day 7. Importantly, immunity to other
betacoronavirus spikes, like HKU1 and OC43, limited the
induction of de novo responses to all SARS-CoV-2 antigens
tested. All patients also developed detectable levels of spike IgG/
IgM and N IgG. Although no significant correlation was found
between pre-exposure to seasonal coronaviruses and induction of
protective antibodies with neutralizing activity, simple linear
regression estimated a negative relationship, and the predicted
line approximated a negative influence on development of de
novo neutralizing antibodies over time. Similarly, baseline anti-
body levels to HKU1 or OC43 spike after SARS-CoV-2 IgG levels
normalization limited the induction of neutralizing antibody
levels after in the follow-up.
While we could not find statistically significant differences for
antibody levels in patients with mild vs. severe disease, the latter
showed a delay in antibody responses. Moreover, anti-SARS-
CoV-2 antibodies inversely correlated with viral loads in
respiratory samples, whereas virus clearance could not be linked
to back-boosting of antibodies toward the S2 subunit of the
seasonal human coronaviruses. Importantly, several reports have
shown cross-reactivity between pre-existing memory T cells to
seasonal coronaviruses and SARS-CoV-225,48 pointing to a
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potential role of heterologous immunity as an additional
mechanism of protection or even differences on COVID-19
outcomes. However, our results allow for a contrasting hypothesis
in which early priming of the memory B cell compartment due to
pre-exposure to seasonal coronaviruses could dampen secondary
responses toward new epitopes of SARS-CoV-2. Nonetheless, all
patients from the BACO cohort developed antibody responses
against SARS-CoV-2 antigens and specific neutralizing anti-
bodies. In addition, SARS-CoV-2 is evolving, and some variants
including 501Y spike mutations have emerged and rapidly spread
in countries, such as UK, South Africa, and Brazil (https://www.
who.int/csr/don/31-december-2020-sars-cov2-variants/en/).
These variants contain mutations that introduce amino acid
changes in RBD residues targeted by neutralizing antibodies and
therefore have functional significance. There is a general concern
on whether new emerging variants (also known as variants of
concern, VOC) could evade immunity generated not only by
previous infections but also vaccination causing a drop on the
effectiveness of COVID-19 vaccines. It is possible that first-
generation COVID-19 vaccines will need to be updated according
to the circulating variants in the future.
Our observation has important impact of on the development
of COVID-19 vaccines and the potential interactions with pre-
existing immunity should be taken into consideration in the
path to optimal vaccines. COVID-19 vaccines in use aim at
the induction of responses against the full-length S protein of
SARS-CoV-249, which is known to contain cross-reactive non-
neutralizing epitopes that are shared with seasonal human beta-
coronaviruses. A similar scenario to our studies in infected people
could be proposed for the vaccines, with some differences due to
the nature of the stimulus itself. Back-boost of cross-reactive
antibody responses might lead to less protective antibodies
directed against non-neutralizing conserved epitopes between the
S antigen of the vaccine and the S proteins of seasonal human
betacoronaviruses50. On the other hand, it is also possible that
cross-reactive antibodies provide protection from severe disease
outcomes by immune mechanisms of action different from those
involved on in vitro virus neutralization, such as antibody-
dependent cytotoxicity. That is the case for broadly cross-reactive
and non-neutralizing anti-influenza antibodies targeting the
conserved stalk domain of the hemagglutinin protein of influenza
viruses. HA stalk antibodies can mediate antibody-dependent cell
cytotoxicity, contributing to protection from disease severity
independently of neutralizing activity51. Whether in vitro non-
neutralizing anti-SARS-CoV-2 antibodies contribute to protec-
tion or disease or are neutral is still not clear.
Our study has several limitations. We comprehensively char-
acterized antigen specificity, neutralization potency, and viral
cross-reactivity against multiple coronaviruses over time. How-
ever, the number of subject enrolled remained relatively small due
to the challenges and restrictions faced by the hospitals during the
initial spread of SARS-CoV-2, underpowering the conclusions of
this study. In addition, all the patients enrolled required hospi-
talization, and the pre-existing immunity of asymptomatic or
mild cases of COVID-19 could not be characterized in this study.
Still, our results demonstrate that the antibody response against
SARS-CoV-2 infection and, potentially vaccination, is influenced
by imprinting of the B cell compartment due to previous
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exposure to seasonal human betacoronaviruses. This is consistent
with additional recent studies33. It will be important to investigate
the potential functional consequences of this imprinting in the
induction of protective immune responses after SARS-CoV-2
infection and vaccination in the long term, and in the very likely
case that the current pandemic evolves into epidemic outbreaks.
Methods
Experimental model and subject details: The BACO cohort. An observational
prospective human cohort study of COVID-19 was carried out during the first
pandemic wave (March–May 2020) of SARS-CoV-2 in Barcelona (Spain) and was
termed the BACO Cohort. A positive case was defined according to international
guidelines when a nasopharyngeal (NP) swab tested positive for SARS-CoV-2 by
reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) upon
hospital admission. All patients or their legally authorized representatives provided
informed consent. Serum and samples were collected at the enrollment in the study
(baseline), and at days 3 and 7 post enrollment. A convalescence sample was
collected from survivors after recovery and hospital discharge with a mean time of
46 days (range, 30–56 days). The total number of serum samples was 116. Data on
demographics, including age and sex, comorbidities, clinical signs and symptoms,
interventions, and outcomes are described in Table 1. Severity of COVID-19 was
assigned following a described severity scale based on oxygen saturation (SpO2),
presence of pneumonia/imaging, oxygen support defined as use of high-flow nasal
cannula (HFNC), non-rebreather mask (NRB), bilevel positive airway pressure
(BIPAP) or mechanical ventilation (MV); and kidney (creatinine clearance, CrCl)
and liver (alanine aminotransferase, ALT) function44: mild (SpO2 > 94% AND no
pneumonia), moderate (SpO2 < 94% AND/OR pneumonia), severe (use of HFNC,
NRB, BIPAP or MV AND no vasopressor use AND CrCl >30 AND ALT < 5x
upper limit of normal) and severe with end-of organ disease (Use of HFNC, NRB,
BIPAP or MV AND vasopressor use OR CrCl >30 or new HD OR ALT < 5x upper
limit of normal).
The study protocol was approved by the Institutional Review Board of
University Hospital of Bellvitge, Barcelona, Spain; and by the Icahn School of
Medicine at Mount Sinai, New York, US.
Cell lines. Vero E6 cells were originally purchased from the American Type
Culture Collection (ATCC, Cat# CRL-1586). Cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) w/ L-glutamate, sodium pyruvate (Corning)
supplemented with 10% fetal bovine serum (FBS), 10 U penicillin per ml, and
10 mg streptomycin per ml. HCT-8 human cells line was obtained from the ATCC
(Cat#CCL-24) and maintained in Roswell Park Memorial Institute 1640 medium
(Gibco) supplemented with 10% FBS, 10 U penicillin per ml, and 10 mg
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streptomycin per ml. Cell lines were supplemented with Normocyn (Invivogen,
Cat. ant-nr-1) to prevent Mycoplasma contamination.
Virus strains. SARS-CoV-2, isolate USA-WA1/2020, was initially obtained from
BEI Resources (Cat#NR-52281) and further propagated in Vero E6 cells52. Human
coronavirus OC43 was obtained from the ATCC (Cat#VR-1558) and propagated
on HCT-8 cells following ATCC recommendations.
Microneutralization assays. Microneutralization (MN) assays for antibody
characterization were performed as described52. Briefly, Vero E6 cells were seeded
in a 96-well cell culture plate with complete Dulbecco’s Modified Eagle Medium
(cDMEM)(Corning) [Penicillin-streptomycin (Corning), non-essential amino acids
(Corning), 10% FBS (Peak)]. The following day, heat-inactivated serum samples
were serially diluted three-fold in 1x minimum essential medium with 2% FBS with
a final volume of 200 µl. 80 µl of serum dilution was transferred to a new 96-well
plate and 600 Tissue Culture Infectious Dose 50 percent per well of SARS-CoV-2
(80 µl/well) and mixed with serum dilution and incubated for 1 h at 37 °C. Then,
cDMEM was removed from Vero e6 cells and 120 µl of virus-serum mixture was
added to the cells. The cells were incubated at 37 °C for 1 h. Virus-serum mixture
was removed from the cells and 100 µl of serum dilutions and 100 µl of 1xMEM
with 2% FBS was added to the cells. The cells were incubated for 24 h and then
fixed with 10% paraformaldehyde (Polysciences) for 24 h at 4 °C. Following fixa-
tion, the cells were washed with phosphate-buffered saline (Corning) with tween-
20 (Fisher) (PBST) and permeabilized with 0.1% Triton X-100 (Fisher) for 15 min
at room temperature. The cells were washed three times using PBST and blocked
with 3% milk in PBST for 1 h at room temperature. Then, the cells were incubated
with mouse antibody 1C7 (anti-SARS N antibody, kindly provided by Dr. Moran)
at a dilution of 1:1000 in 1% milk in PBST and incubated for 1 h at room tem-
perature. The cells were washed three times with PBST. Then, the cells were
incubated with goat anti-mouse IgG-HRP (Abcam, Cat. ab6823) at a dilution of
1:10,000 in 1% milk in PBST and incubated for 1 h at room temperature. The cells
were washed three times with PBST and TMBE Elisa peroxidase substrate
(Rockland) was added. After 15 min incubation, sulfuric acid 4.0 N (Fisher) was
added to stop the reaction and the readout was done using a Synergy H1 plate
reader (BioTek) at an OD450.
Recombinant proteins. The recombinant spike protein and recombinant RBD of
SARS-CoV-2 were generated and expressed as previously described in detail52,53. In
brief, the mammalian cell codon-optimized nucleotide sequence for the soluble ver-
sion of the spike protein (amino acids 1-1213) including a C-terminal thrombin
cleavage site, signal peptide, hexahistidine tag and T4 foldon trimerization domain
were cloned into pCAGGS mammalian expression vector. The sequence of the spike
protein was additionally modified to remove the polybasic cleavage site and two
proline residues introduced to increase protein stability. The nucleotide sequence for
the RBD (amino acids 319-541) including a signal peptide was cloned into pCAGGS.
RBD mutants were generated in the pCAGGS RBD construct by changing single
residues using site-directed mutagenesis. The expression plasmids encoding for the
spike of common human coronavirus 229E, OC43, and HKU1 were obtained from
the NIH (kindly provided by Kizzmekia Corbett and Barney Graham) and the
expression plasmid encoding for SARS-CoV-2 NP was constructed at Mount Sinai.
The recombinant proteins were expressed in Expi293F cells (Thermo Fisher) using
the ExpiFectamine 293 Transfection Kit (Thermo Fisher) according to the manu-
facturer’s protocol. Cell supernatant was harvested, and the proteins purified using
Ni-NTA Agarose (Qiagen). The proteins were concentrated in Amicon centrifugal
units (EMDMilipore) and correct size confirmed by reducing sodium dodecyl sulfate-
polyacrylamide gel electrophoreses. The recombinant S1 subunit of HKU1 was
purchased from Sino Biological (Cat. 40021-V08H).
Enzyme-linked immunosorbent assay (ELISA). Ninety-six-well microtiter plates
(Thermo Fisher) were coated with 50 μL recombinant protein (RBD, SARS-CoV-2
full-length spike, SARS-CoV-2 NP, OC43 spike, 229E spike, or HKU1 spike,
respectively) at a concentration of 2 µg/mL overnight, 4 °C. The next day, the plates
were washed three times with PBS (phosphate-buffered saline; Gibco) containing
0.1% Tween-20 (T-PBS, Fisher Scientific) using an automatic plate washer (Bio-
Tek). After washing, the plates were blocked for 1 h at room temperature with 200
µl blocking solution (PBS-T with 3% (w/v) milk powder (American Bio)) per well.
The blocking solution was removed and serum samples diluted to a starting
concentration of 1:80, serially diluted 1:3 in PBS-T supplemented with 1% (w/v)
milk powder and incubated at room temperature for 2 h. The plates were washed
three times with PBS-T and 50 µl anti-human IgG (Fab-specific) horseradish
peroxidase antibody (HRP, Sigma, Cat. A0293) diluted 1:3,000 in PBS-T containing
1% milk powder was added to all wells and incubated for 1 h at room temperature.
The plates were washed three times using the plate washer and 100 μL SigmaFast o-
phenylenediamine dihydrochloride (Sigma) was added to all wells for 10 min. The
enzymatic reaction was stopped with 50 μL 3M hydrochloric acid (Thermo Fisher)
per well and the plates read at a wavelength of 490 nm with a plate reader (BioTek).
The results were recorded in Microsoft Excel and AUC values were computed by
plotting normalized OD values against the reciprocal serum sample dilutions for
ELISAs in GraphPad Prism.
Hemagglutination inhibition (HAI) assay. Serum samples were incubated over-
night with receptor-destroying enzyme (RDE; Denka Seiken) for 16–18 h in a 37 °C
water bath. Three volumes (relative to serum) of 2.5% sodium citrate solution were
added and the resulting solution was heat inactivated at 56 °C in a water bath (30
min). Final serum dilutions were adjusted to 1:10 in PBS. OC43 virus was diluted to
a final concentration of 8 HA units/50 µL in fluorescent treponemal antibody HA
buffer (BD Biosciences). Twofold dilutions of RDE treated serum (25 µL) were
incubated with equal amount of the virus at 8 HA units/50 µL (30 min, room
temperature). Chicken red blood cells (RBCs) (Lampire Biological) at 0.5% in HA
buffer (50 µL) were added and incubated 45 min at 4 °C. The HAI titer was
determined by taking the reciprocal dilution of the last well in which serum
inhibited the HA of RBCs.
Viral loads and qRT-PCR. To detect SARS-CoV-2 RNA in nasal swabs, a modified
version of the CDC 2019-nCoV real-time RT-qPCR was used. Primers and probes
were commercially available (Integrated DNA Technologies, cat. 10006713, RUO
Kit). SARS-CoV-2 primer and probe sets consisted of two 2019-nCoV-specific sets
(N1, N2). A third primer set was used to detect host cellular RNaseP. Reactions
were run using the QuantiFast Pathogen RT-PCR+ IC Kit (QIAGEN, cat. 211454).
A list of all primers used, including the names and sequences, is shown in Sup-
plementary Table 3. Assays were run using USA/WA-1/2020 SARS-CoV-2 RNA as
a positive control (20,000 genome copies per reaction) and nuclease-free water as a
non-template control in a 384-well format. Reactions were performed in duplicate
using the following cycling conditions on the Roche LightCycler 480 Instrument II
(Roche Molecular Systems, 05015243001): 50 °C for 20 min, 95 °C for 1 s, 95 °C for
5 min, followed by 45 cycles of 95 °C for 15 s and 60 °C for 45 s. Limit of detection
for SARS-CoV-2 was determined by using a commercially available plasmid
control (Integrated DNA Technologies, cat. 10006625).
Multiple sequences alignment and conservation scores. MSA to determine the
spike protein sequence identity among SARS-CoV-2 (NC_045512.2), and the
human endemic betacoronaviruses HKU1 (YP_173238) and OC43
(YP_009555241.1), and alphacoronavirus 229E (NP_073551.1) was performed with
ClustalW. Conservation patterns and scores of the spike protein of SARS-CoV-2
were determined using the ConSurf server (https://consurf.tau.ac.il/). Briefly, a
MSA of 150 homologous sequences was constructed using MAFFT. Position-
specific conservation scores were computed using an empirical Bayesian algorithm
and divided into a discrete scale of nine grades. The conservation scores were
projected onto the SARS-CoV-2 spike protein in the closed state (PDB ID 6VXX)
as a reference.
Quantification and statistical analysis. All immune assay values were log10-
transformed to improve linearity. The GMT and 95% confidence intervals (CI 95%)
were computed by taking the exponent (log10) of the mean and of the lower and
upper limits of the 95% CI of the log10‐transformed titers. Fold rise was calculated
as the ratio between days 3, 7 or convalescent antibody value to baseline levels.
GMFR was computed by taking the exponent (log10) of the mean fold rise and of
the lower and upper limits of the CI 95% of the log10‐transformed titers. Statistical
significance was established at p < 0.05. All reported p values are based on two‐tailed
tests. Correlation (Pearson), linear regression, local regression fit-line and related-
sample multiple comparison (Friedman’s two-way analysis of variance by ranks,
also known as Friedman’s two-way ANOVA, and pairwise comparison adjusted by
Bonferroni correction) were performed using IBM SPSS Statistics (version 26).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data are available in the manuscript or the supplementary materials. Source data are
provided with this paper. The accession codes for the Structure of the SARS-CoV-2 spike
glycoprotein (closed state) EMD: 21452 and PDB: 6VXX. Source data are provided with
this paper.
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